Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yimu Angong is a Traditional Chinese Medicine (TCM) formulation developed by Shanxi Yabao Pharmaceutical Group Co., Ltd. It is primarily indicated for the treatment of uterine bleeding, including postpartum hemorrhage and persistent lochia. The formulation is centered on *Leonurus japonicus* (Motherwort), which is recognized in TCM for its ability to promote blood circulation, resolve blood stasis, and regulate uterine function. Mechanistically, the active components, such as leonurine, stimulate uterine smooth muscle contractions and improve local blood flow, thereby facilitating the expulsion of retained tissues and controlling excessive bleeding. It is commonly administered in granule form for oral consumption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yimu Angong.